 Medscape | National Study: 30% of Chemotherapy Used Off-Label Medscape But the study also turned up some disconcerting findings about the high rate of off-label prescribing of some agents, especially gemcitabine (Gemzar, Lilly), rituximab (Rituxan, Genentech), and bevacizumab (Avastin, Genentech), Dr. Krzyzanowska notes. |
